Insider Selling: Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the sale, the insider directly owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. The trade was a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Denali Therapeutics Trading Down 1.7%

DNLI stock opened at $24.40 on Friday. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $27.30. The company has a market capitalization of $3.90 billion, a PE ratio of -8.59 and a beta of 1.01. The company’s 50-day simple moving average is $24.04 and its 200 day simple moving average is $21.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same period last year, the business earned ($0.72) EPS. As a group, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.59 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $39.00 price target on shares of Denali Therapeutics in a research note on Monday, May 11th. Wall Street Zen upgraded Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group raised their price objective on Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft upped their target price on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Morgan Stanley increased their target price on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.92.

Institutional Trading of Denali Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Denali Therapeutics in the second quarter valued at approximately $26,000. Headlands Technologies LLC acquired a new position in Denali Therapeutics during the second quarter valued at approximately $26,000. Global Retirement Partners LLC bought a new stake in Denali Therapeutics during the second quarter worth $28,000. Johnson Financial Group Inc. bought a new stake in Denali Therapeutics during the third quarter worth $29,000. Finally, State of Wyoming acquired a new stake in shares of Denali Therapeutics in the 2nd quarter valued at $29,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.